LIVERPOOL LIFE SCIENCE ACCELERATOR LIMITED

Registered charity 1200750 · accounts filings on the Charity Commission register

Get email alerts for this charity

Latest income
£1.1m
Latest spending
£1.1m
Registered
2022
Accounts read
FY2025

Financial health, per its FY2025 accounts

The accounts state that the charity reported a net outgoing resource of £16k and holds negative free reserves of £187k, driven by depreciation and an unrealized loss on an interest rate swap. The trustees confirm that loan covenants are being met and rely on the parent company's support and cash pooling facility to maintain adequate resources for the foreseeable future.

What the accounts disclose

Reserves position: below the charity's own stated reserves policy
Total and free reserves are -£187k (2024 : -£132k).
Per its FY2025 accounts as filed with the Charity Commission.
Related-party transaction: Rents received from parent company
During 2025, rents totalling £995k were received from LLSA’s parent company Liverpool School of Tropical Medicine (LSTM)(2024 : £1,039k) ; As at 31 July 2025 there was an outstanding inter-company balance of £260k debtor owed by LSTM relating rents owed (2024 : £476k) — page 24
During 2025, no loans were made by LLSA’s parent company Liverpool School of Tropical Medicine (LSTM) (2024 : £Nil) and interest of £508k was paid (2024 : £564k); As at 31 July 2025 there was an outstanding inter-company balance of £49k creditor owed by LLSA in relation to loan interest (2024 : £50k) — page 25
Per its FY2025 accounts as filed with the Charity Commission.
Related-party transaction: Interest paid on intercompany loan
During 2025, rents totalling £995k were received from LLSA’s parent company Liverpool School of Tropical Medicine (LSTM)(2024 : £1,039k) ; As at 31 July 2025 there was an outstanding inter-company balance of £260k debtor owed by LSTM relating rents owed (2024 : £476k) — page 24
During 2025, no loans were made by LLSA’s parent company Liverpool School of Tropical Medicine (LSTM) (2024 : £Nil) and interest of £508k was paid (2024 : £564k); As at 31 July 2025 there was an outstanding inter-company balance of £49k creditor owed by LLSA in relation to loan interest (2024 : £50k) — page 25
Per its FY2025 accounts as filed with the Charity Commission.
Related-party transaction: Rents received from sister company
During 2025, rents totalling £995k were received from LLSA’s parent company Liverpool School of Tropical Medicine (LSTM)(2024 : £1,039k) ; As at 31 July 2025 there was an outstanding inter-company balance of £260k debtor owed by LSTM relating rents owed (2024 : £476k) — page 24
During 2025, no loans were made by LLSA’s parent company Liverpool School of Tropical Medicine (LSTM) (2024 : £Nil) and interest of £508k was paid (2024 : £564k); As at 31 July 2025 there was an outstanding inter-company balance of £49k creditor owed by LLSA in relation to loan interest (2024 : £50k) — page 25
Per its FY2025 accounts as filed with the Charity Commission.

Accounts audited by Crowe U.K. LLP. Discloses 4 of 6 completeness components.

Structured financials (annual return, FY ending 31/07/2025)

Total income
£1.1m
Total spending
£1.1m
Reserves (reported)
£187k
Employees
0

Reported reserves equal ~2.0 months of spending — in the bottom quarter for charities its size (median 4.8 months; benchmarks).

Trustees

Trustee list from the Charity Commission register (current, not historical).

Operates in: Throughout England And Wales

Income and spending

Financial year endIncomeSpending
31/07/2025£1.1m£1.1m
31/07/2024£1.2m£1.1m
31/07/2023£746k£745k

Common questions

Is LIVERPOOL LIFE SCIENCE ACCELERATOR LIMITED financially healthy?

The accounts state that the charity reported a net outgoing resource of £16k and holds negative free reserves of £187k, driven by depreciation and an unrealized loss on an interest rate swap. The trustees confirm that loan covenants are being met and rely on the parent company's support and cash pooling facility to maintain adequate resources for the foreseeable future. Its FY2025 accounts were audited by Crowe U.K. LLP.